Opens in a new tab or window For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban.

apixaban), which is taken by nearly 4 million Medicare beneficiaries and in 2024 had a list price of about $550 per month – within the typical range for branded, non-specialty drugs. The drug's ...

For example, apixaban (a DOAC) has a lower risk of significant bleeding than warfarin, so for many older patients with AF, this would be an excellent medication. Our findings highlight the ...

A SUBGROUP analysis of the ARTESiA trial suggests that apixaban provides a significant reduction in stroke or systemic embolism in people with subclinical atrial fibrillation and a history of stroke ...